Status:
UNKNOWN
Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Pediatric Solid Tumors
Eligibility:
All Genders
1-22 years
Brief Summary
Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survi...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Patients of pediatric age up to 22 years included at the time of molecular analysis
- Histological carcinological diagnosis performed at HUS
- Carcinological follow-up performed at HUS
- Patients with a solid tumor of unfavorable prognosis, refractory or in relapse
- Molecular analysis performed on tumor or blood samples
- Adult patients who do not object to the re-use of their personal data for medical research purposes
- Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes.
- Criteria for non-inclusion
- Molecular biology results not usable due to poor sample quality or insufficient genetic material
- Patients who have expressed their opposition to participate in the study
- Parental authority holders who have expressed their opposition to participate in the study
Exclusion
Key Trial Info
Start Date :
June 20 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT06171971
Start Date
June 20 2022
End Date
December 1 2023
Last Update
December 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'onco-hématologie pédiatrique - CHU de Strasbourg - France
Strasbourg, France, 67091